Aligos Therapeutics (ALGS) announced completion of enrollment in both Phase 2 B-SUPREME trial cohorts—HBeAg+ (Part 1a) and HBeAg- (Part 2a)—in adults with chronic hepatitis B (HBV). The update is a positive execution milestone for the program, though no efficacy or readout data were provided.
Aligos Therapeutics (ALGS) announced completion of enrollment in both Phase 2 B-SUPREME trial cohorts—HBeAg+ (Part 1a) and HBeAg- (Part 2a)—in adults with chronic hepatitis B (HBV). The update is a positive execution milestone for the program, though no efficacy or readout data were provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.18
Ticker Sentiment
